MétaCan
Menu
Back to cohort
Record W4407710006 · doi:10.1080/23995270.2025.2466380

Orphan drugs approved in Canada: availability and additional therapeutic value

2025· article· en· W4407710006 on OpenAlexaffabout
Joel Lexchin

Bibliographic record

VenueFuture Rare Diseases · 2025
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicPharmaceutical Economics and Policy
Canadian institutionsYork UniversityUniversity of Toronto
Fundersnot available
KeywordsOrphan drugValue (mathematics)MedicineBusinessPharmacologyMathematicsStatisticsBiologyBioinformatics

Abstract

fetched live from OpenAlex

Orphan drugs approved in Canada: availability and additional therapeutic valuein their recent article in expert opinion on rare drugs, which is no longer accepting submissions, on the accessibility of orphan drugs in Canada, rawson and Adams conclude that "Canadians with rare disorders continue to suffer from a lack of timely and equitable access to innovative treatments" [1].they based this conclusion on an analysis of the percent of orphan drugs approved by either the Food and drug Administration (FdA) or the european Medicines Agency (eMA) from 2015 to 2020 that were submitted to health Canada, the time taken for these drugs to be evaluated by both the Canadian Agency for drugs and technologies in health (CAdth) and the pan-Canadian Pharmaceutical Alliance, the recommendations from these two agencies and finally how many of the drugs were eventually listed on provincial formularies.this letter to the editor examines the biases in what data rawson and Adams left out and their interpretation of their data.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.514
Threshold uncertainty score0.998

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.228
Teacher spread0.215 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueFuture Rare DiseasesSame topicPharmaceutical Economics and PolicyFrench-language works237,207